Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib for Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Patients

    Not recruiting

    2 1 1 1
    Italy
  • Study on the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Sodium Thiosulfate for Ovarian Cancer Patients Undergoing Surgery

    Not recruiting

    3 1 1 1
    Belgium France
  • Study Comparing Paclitaxel, Carboplatin, and Oregovomab with Paclitaxel, Carboplatin, and Placebo for Patients with Advanced Ovarian Cancer

    Not recruiting

    3 1
    Investigated Drugs:
    Belgium Czechia Hungary Italy Spain
  • Study of Pembrolizumab and Chemotherapy for Patients with Recurrent Platinum-Sensitive Low-Grade Serous Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Germany
  • Study of Farletuzumab Ecteribulin vs. Chemotherapy for Women with Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Not recruiting

    2 1 1 1
    Belgium Italy Spain
  • Study of Pembrolizumab, MK-4830, and Chemotherapy for Patients with High-Grade Serous Ovarian Cancer

    Not recruiting

    2 1 1 1
    Belgium Italy Poland Spain
  • Study on Treatment for Recurrent Platinum-Sensitive Ovarian, Peritoneal, or Fallopian Tube Cancer Using Carboplatin and Mirvetuximab Soravtansine in Eligible Patients

    Not recruiting

    2 1 1 1
    Belgium Ireland Spain
  • Study of Mirvetuximab Soravtansine compared to standard chemotherapy in women with platinum-resistant advanced ovarian cancer with high folate receptor expression

    Not recruiting

    3 1 1 1
    France
  • Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Not recruiting

    4 1 1 1
    Czechia Finland France Germany Greece Italy +3